The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
Publications
Pulmonary complications of novel antineoplastic agents for solid tumors.
Chest 2008 Feb;133;528-38 — 2008 Feb — 528-38
Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
Cancer treatment reports 1985 Apr;69;439-41 — 1985 Apr — 439-41
Hypersensitivity reactions to teniposide (VM-26): an analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986 Aug;4;1262-9 — 1986 Aug — 1262-9
Teniposide-induced hypersensitivity reactions in children.
Lancet (London, England) 1989 Jul 01;2;55 — 1989 Jul 01 — 55
Anaphylactic reactions to teniposide.
Lancet (London, England) 1989 Feb 18;1;394 — 1989 Feb 18 — 394
Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia.
Cancer 1991 Feb 15;67;1070-5 — 1991 Feb 15 — 1070-5